In addition, BRAF-WT patients achieved a higher rate of median early tumor shrinkage (ETS) at time of first radiological reassessment in comparison with BRAF-MT patients [85.2% (95% CI 72.9–93.4%) vs. 33.3% (95% CI 9.9–65.1%); p = 0.001]. The gene discussed is BRAF; the disease is neoplasm.